Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Authors

  • Behfar Ehdaie Department of Urology, University of Virginia, Charlottesville, VA
  • Steven C. Smith Department of Molecular Physiology, University of Virginia, Charlottesville, VA
  • Dan Theodorescu Department of Urology; Department of Molecular Physiology; Paul Mellon Urologic Cancer Institute, University of Virginia, Charlottesville, VA

DOI:

https://doi.org/10.5489/cuaj.1204

Abstract

The past decade has provided an improved understanding of the
molecular mechanism of bladder cancer by defining distinct pathways
in tumorigenesis and progression. Advances in technologies,
such as high-throughput transcript profiling, microarrays and
proteomics, offer a systematic approach to identifying targets for
bladder cancer diagnostics and drug discovery. This review presents
a select outline of the advances in the development of biomarkers
and targets for patient prognosis and therapy selection.
This paper describes a representative cohort of recent studies that
have the potential to significantly impact the management of muscle
invasive and metastatic urothelial carcinoma of the bladder.
Space constraints do not permit this review to be comprehensive
and we apologize to the authors whose work we do not cite.

Downloads

Download data is not yet available.

Author Biographies

Behfar Ehdaie, Department of Urology, University of Virginia, Charlottesville, VA

Steven C. Smith, Department of Molecular Physiology, University of Virginia, Charlottesville, VA

Dan Theodorescu, Department of Urology; Department of Molecular Physiology; Paul Mellon Urologic Cancer Institute, University of Virginia, Charlottesville, VA

Downloads

How to Cite

Ehdaie, B., Smith, S. C., & Theodorescu, D. (2013). Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. Canadian Urological Association Journal, 3(6-S4), S232-S236. https://doi.org/10.5489/cuaj.1204

Issue

Vol. 3 No. 6-S4 (2009): CUAJ December Suppl 4

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.